Literature DB >> 34359664

Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176".

Ashley M Hopkins1, Ganessan Kichenadasse1,2, Ahmad Y Abuhelwa1, Ross A McKinnon1, Andrew Rowland1, Michael J Sorich1.   

Abstract

We thank Auclin et al. [...].

Entities:  

Year:  2021        PMID： 34359664     DOI： 10.3390/cancers13153763

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  1 in total

1.  Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Satomi Tanaka; Junji Uchino; Takashi Yokoi; Takashi Kijima; Yasuhiro Goto; Yoshifumi Suga; Yuki Katayama; Ryota Nakamura; Kenji Morimoto; Akira Nakao; Makoto Hibino; Nozomi Tani; Takayuki Takeda; Hiroyuki Yamaguchi; Yusuke Tachibana; Chieko Takumi; Noriya Hiraoka; Masafumi Takeshita; Keisuke Onoi; Yusuke Chihara; Ryusuke Taniguchi; Takahiro Yamada; Yohei Matsui; Osamu Hiranuma; Yoshie Morimoto; Masahiro Iwasaku; Shinsaku Tokuda; Yoshiko Kaneko; Tadaaki Yamada; Koichi Takayama
Journal:  Diagnostics (Basel)       Date:  2022-02-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.